UniProt G0SFD1
Chaetomium alpha glucosidase (G0SFD1)
Chaetomium alpha glucosidase (UniProt G0SFD1): 31 experimental structures on GenesisL1, 32 ligands bound, 472 pockets. Binding sites, pockets, druggability and 3D structures in GL1X.
- UniProt
- G0SFD1
- Protein
- Chaetomium alpha glucosidase
- Experimental structures
- 31
- Predicted models
- 0
- Ligands
- 32
- Pockets
- 472 · 29 records with a druggable one
Structures
31 records of G0SFD1 in the MolNFT archive: 31 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 7R6J | Co-crystal structure of Chaetomium glucosidase with compound 1 | x-ray diffraction | A, B | NAG, 2I7, SO4 | 15 (best 0.81) |
| 7RD2 | Co-crystal structure of Chaetomium glucosidase with compound 2 | x-ray diffraction | A, B | NAG, 5X7, SO4 | 15 (best 0.81) |
| 7REV | Co-crystal structure of Chaetomium glucosidase with compound 3 | x-ray diffraction | A, B | 5RK, SO4, NAG | 18 (best 0.81) |
| 7T66 | Co-crystal structure of Chaetomium glucosidase with compound UV-4 | x-ray diffraction | A, B | 6A9, SO4, NAG | 16 (best 0.81) |
| 7T68 | Co-crystal structure of Chaetomium glucosidase with compound UV-5 | x-ray diffraction | A, B | GII, SO4, NAG | 16 (best 0.82) |
| 7T6W | Crystal structure of Chaetomium Glucosidase I (apo) | x-ray diffraction | A, B | NAG, SO4 | 16 (best 0.81) |
| 7T8V | Co-crystal structure of Chaetomium glucosidase I with EB-0159 | x-ray diffraction | A, B | W9Y, NAG, SO4 | — |
| 8E3J | Co-crystal structure of Chaetomium glucosidase with compound 4 | x-ray diffraction | A, B | UGO, SO4, NAG | — |
| 8E3P | Co-crystal structure of Chaetomium glucosidase with compound 5 | x-ray diffraction | A, B | UF6, SO4, NAG | 19 (best 0.76) |
| 8E4I | Co-crystal structure of Chaetomium glucosidase with compound 6 | x-ray diffraction | A, B | UIJ, SO4, NAG | 15 (best 0.81) |
| 8E4K | Co-crystal structure of Chaetomium glucosidase with compound 7 | x-ray diffraction | A, B | UIO, SO4, NAG | 16 (best 0.81) |
| 8E4Z | Co-crystal structure of Chaetomium glucosidase with compound 8 | x-ray diffraction | A, B | UKF, SO4, NAG | 15 (best 0.81) |
| 8E5U | Co-crystal structure of Chaetomium glucosidase with compound 9 | x-ray diffraction | A, B | UPH, SO4, NAG | 16 (best 0.81) |
| 8E6G | Co-crystal structure of Chaetomium glucosidase with compound 10 | x-ray diffraction | A, B | UQH, SO4, NAG | 17 (best 0.81) |
| 8ECW | Co-crystal structure of Chaetomium glucosidase with compound 11 | x-ray diffraction | A, B | X5B, SO4, NAG | 17 (best 0.81) |
| 8EGV | Co-crystal structure of Chaetomium glucosidase with compound 12 | x-ray diffraction | A, B | WJF, SO4, NAG | 15 (best 0.81) |
| 8EHP | Co-crystal structure of Chaetomium glucosidase with compound 13 | x-ray diffraction | A, B | WJO, NAG, SO4 | 18 (best 0.81) |
| 8EID | Co-crystal structure of Chaetomium glucosidase with compound 14 | x-ray diffraction | A, B | WJT, SO4, NAG | 15 (best 0.80) |
| 8EKN | Co-crystal structure of Chaetomium glucosidase with compound 15 | x-ray diffraction | A, B | WLQ, SO4, NAG | 15 (best 0.81) |
| 8ELE | Co-crystal structure of Chaetomium glucosidase with compound 16 | x-ray diffraction | A, B | WM0, SO4, NAG | 16 (best 0.81) |
| 8EPJ | Co-crystal structure of Chaetomium glucosidase with compound 17 | x-ray diffraction | A, B | WQU, NAG, SO4 | 18 (best 0.82) |
| 8EPO | Co-crystal structure of Chaetomium glucosidase with compound 18 | x-ray diffraction | A, B | WQZ, SO4, NAG | 17 (best 0.82) |
| 8EQ7 | Co-crystal structure of Chaetomium glucosidase with compound 20 | x-ray diffraction | A, B | WT0, NAG, SO4 | 18 (best 0.81) |
| 8EQX | Co-crystal structure of Chaetomium glucosidase with compound 21 | x-ray diffraction | A, B | NAG, WT5, SO4 | 16 (best 0.81) |
| 8ER4 | Co-crystal structure of Chaetomium glucosidase with compound 23 | x-ray diffraction | A, B | XG5, SO4, NAG | 16 (best 0.75) |
| 8ETL | Co-crystal structure of Chaetomium glucosidase with compound 24 | x-ray diffraction | A, B | VND, SO4 | 15 (best 0.81) |
| 8ETO | Co-crystal structure of Chaetomium glucosidase with compound 25 | x-ray diffraction | A, B | W9V, NAG, SO4 | 16 (best 0.81) |
| 8EUD | Co-crystal structure of Chaetomium glucosidase with compound 22 | x-ray diffraction | A, B | WUR, SO4, NAG | 14 (best 0.81) |
| 8EUR | Co-crystal structure of Chaetomium glucosidase with compound 26 | x-ray diffraction | A, B | WAS, SO4 | 16 (best 0.81) |
| 8EUT | Co-crystal structure of Chaetomium glucosidase with compound 27 | x-ray diffraction | A, B | WV5, SO4, NAG | 19 (best 0.76) |
| 8EUX | Co-crystal structure of Chaetomium glucosidase with compound 28 | x-ray diffraction | A, B | WV9, SO4, NAG | 17 (best 0.81) |
Ligands
- SO4 · Sulfate ion · in 31 records
- NAG · 2-acetamido-2-deoxy-beta-D-glucopyranose · in 29 records
- 2I7 · (2R,3R,4R,5S)-2-(hydroxymethyl)-1-[(3-{[3-methyl-5-(pyrimidin-2-yl)anilino]methyl}phenyl)methyl]piperidine-3,4,5-triol · in 1 record
- 5RK · (2R,3R,4R,5S)-1-[(4-{[4-(furan-2-yl)-2-methylanilino]methyl}phenyl)methyl]-2-(hydroxymethyl)piperidine-3,4,5-triol · in 1 record
- 5X7 · (2R,3R,4R,5S)-1-{[4-({4-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-2-nitroanilino}methyl)phenyl]methyl}-2-(hydroxymethyl)piperidine-3,4,5-triol · in 1 record
- 6A9 · N-9'-methoxynonyl-1-deoxynojirimycin · in 1 record
- GII · (2R,3R,4R,5S)-1-[6-(4-azido-2-nitroanilino)hexyl]-2-(hydroxymethyl)piperidine-3,4,5-triol · in 1 record
- UF6 · (2S,3S,4S,5R)-2-(hydroxymethyl)-1-{6-[3-nitro-5-(pyridin-4-yl)anilino]hexyl}piperidine-3,4,5-triol · in 1 record
- UGO · (2R,3R,4R,5S)-2-(hydroxymethyl)-1-{6-[2-nitro-4-(pyrimidin-2-yl)anilino]hexyl}piperidine-3,4,5-triol · in 1 record
- UIJ · (2R,3R,4R,5S)-2-(hydroxymethyl)-1-(6-{[(4P)-4-(5-methyl-1,2,4-oxadiazol-3-yl)-2-nitrophenyl]amino}hexyl)piperidine-3,4,5-triol · in 1 record
- UIO · (2R,3R,4R,5S)-2-(hydroxymethyl)-1-[6-({(4M)-4-[2-(morpholin-4-yl)pyrimidin-4-yl]-2-nitrophenyl}amino)hexyl]piperidine-3,4,5-triol · in 1 record
- UKF · (2R,3R,4R,5S)-1-(6-{[(4P)-4-(5-cyclobutyl-1,2,4-oxadiazol-3-yl)-2-nitrophenyl]amino}hexyl)-2-(hydroxymethyl)piperidine-3,4,5-triol · in 1 record
- UPH · (2R,3R,4R,5S)-2-(hydroxymethyl)-1-(6-{2-nitro-4-[(1R,5S)-3-oxa-8-azabicyclo[3.2.1]octan-8-yl]anilino}hexyl)piperidine-3,4,5-triol · in 1 record
- UQH · (2R,3R,4R,5S)-1-(6-{[(5M)-3-cyclopropyl-5-(pyridazin-3-yl)phenyl]amino}hexyl)-2-(hydroxymethyl)piperidine-3,4,5-triol · in 1 record
- VND · (1S,2S,3R,4S,5S)-5-(butylamino)-1-(hydroxymethyl) cyclohexane-1,2,3,4-tetrol · in 1 record
- W9V · (1S,2S,3R,4S,5S)-1-(hydroxymethyl)-5-{[(5Z)-6-{[2-nitro-4-(2H-1,2,3-triazol-2-yl)phenyl]amino}hex-5-en-1-yl]amino}cyclohexane-1,2,3,4-tetrol · in 1 record
- W9Y · (1S,2S,3R,4S,5S)-1-(hydroxymethyl)-5-[(6-{[2-nitro-4-(1H-1,2,3-triazol-1-yl)phenyl]amino}hexyl) amino]cyclohexane-1,2,3,4-tetrol · in 1 record
- WAS · 2-{[2-nitro-4-(triazan-1-yl)phenyl]amino}ethyl (2-{[(1S,2S,3R,4S,5S)-2,3,4,5-tetrahydroxy-5-(hydroxymethyl)cyclohexyl]amino}ethyl)carbamate · in 1 record
- WJF · (2R,3R,4R,5S)-1-{2-[4-(2-{[(5M)-3-chloro-5-(1,2,4-oxadiazol-3-yl)phenyl]amino}ethyl)phenyl]ethyl}-2-(hydroxymethyl)piperidine-3,4,5-triol · in 1 record
- WJO · (2R,3R,4R,5S)-2-(hydroxymethyl)-1-[(4-{[4-(morpholin-4-yl)anilino]methyl}phenyl)methyl]piperidine-3,4,5-triol · in 1 record
- WJT · (2R,3R,4R,5S)-2-(hydroxymethyl)-1-{[4-({[(5P)-3-(methanesulfonyl)-5-(pyridazin-3-yl)phenyl]amino}methyl)phenyl]methyl}piperidine-3,4,5-triol · in 1 record
- WLQ · (2R,3R,4R,5S)-2-(hydroxymethyl)-1-{[4-({[(5P)-3-methyl-5-(pyridazin-3-yl)phenyl]amino}methyl)phenyl]methyl}piperidine-3,4,5-triol · in 1 record
- WM0 · (2R,3R,4R,5S)-2-(hydroxymethyl)-1-{[4-({2-nitro-4-[(1R,5S)-3-oxa-8-azabicyclo[3.2.1]octan-8-yl]anilino}methyl)phenyl]methyl}piperidine-3,4,5-triol · in 1 record
- WQU · (2R,3R,4R,5S)-2-(hydroxymethyl)-1-[(3-{[4-(morpholin-4-yl)-2-nitroanilino]methyl}phenyl)methyl]piperidine-3,4,5-triol · in 1 record
- WQZ · (3P)-3-(5,6-dihydro-1,4-dioxin-2-yl)-5-{[(3-{[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]methyl}phenyl)methyl]amino}benzonitrile · in 1 record
- WT0 · (2R,3R,4R,5S)-1-[(3-{[3-bromo-5-(methanesulfonyl)anilino]methyl}phenyl)methyl]-2-(hydroxymethyl)piperidine-3,4,5-triol · in 1 record
- WT5 · (2R,3R,4R,5S)-2-(hydroxymethyl)-1-{[6-({[(5M)-3-methyl-5-(1H-pyrrol-2-yl)phenyl]amino}methyl)pyridin-2-yl]methyl}piperidine-3,4,5-triol · in 1 record
- WUR · (2R,3R,4R,5S)-2-(hydroxymethyl)-1-{6-[2-methyl-5-(pyrimidin-2-yl)-1H-benzimidazol-1-yl]hexyl}piperidine-3,4,5-triol · in 1 record
- WV5 · (2R,3R,4R,5S)-1-[8-(furan-2-yl)octyl]-2-(hydroxymethyl)piperidine-3,4,5-triol · in 1 record
- WV9 · (2R,3R,4R,5S)-2-(hydroxymethyl)-1-{5-[4-(2-methoxyethyl)phenyl]pentyl}piperidine-3,4,5-triol · in 1 record
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.